|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 38/17 | (2006.01) |
| A61P 27/02 | (2006.01) |
| (11) | Number of the document | 3716992 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18825837.0 |
| Date of filing the European patent application | 2018-11-29 | |
| (97) | Date of publication of the European application | 2020-10-07 |
| (45) | Date of publication and mention of the grant of the patent | 2022-08-10 |
| (46) | Date of publication of the claims translation | 2022-09-12 |
| (86) | Number | PCT/US2018/063025 |
| Date | 2018-11-29 |
| (87) | Number | WO 2019/108770 |
| Date | 2019-06-06 |
| (30) | Number | Date | Country code |
| 201762593033 P | 2017-11-30 | US | |
| 201862644425 P | 2018-03-17 | US | |
| 201862748782 P | 2018-10-22 | US |
| (72) |
VITTI, Robert L. , US
BERLINER, Alyson J. , US
CHU, Karen , US
|
| (73) |
Regeneron Pharmaceuticals, Inc. ,
777 Old Saw Mill River Road, Tarrytown, NY 10591,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | VEGF antagonisto panaudojimas akių angiogeninių sutrikimų gydymui |
| USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS |
| Payment date | Validity (years) | Amount | |
| 2025-10-22 | 8 | 185.00 EUR |
| 2026-11-29 |